Compass Therapeutics Files 8-K
Ticker: CMPX · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1738021
| Field | Detail |
|---|---|
| Company | Compass Therapeutics, Inc. (CMPX) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $127 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, company-update
TL;DR
Compass Therapeutics filed an 8-K on Jan 8, 2025, updating on ops and financials.
AI Summary
Compass Therapeutics, Inc. filed an 8-K on January 8, 2025, reporting on results of operations, financial condition, and other events. The filing also includes financial statements and exhibits. The company was formerly known as Olivia Ventures, Inc. before a name change on April 19, 2018.
Why It Matters
This 8-K filing provides an update on Compass Therapeutics' operational and financial status, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- Compass Therapeutics, Inc. (company) — Registrant
- Olivia Ventures, Inc. (company) — Former company name
- January 8, 2025 (date) — Date of earliest event reported
- April 19, 2018 (date) — Date of name change
- 80 Guest Street, Suite 601 Boston, Massachusetts 02135 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Compass Therapeutics, Inc.?
The primary purpose is to report on the company's results of operations and financial condition, as well as other events, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on January 8, 2025.
What was Compass Therapeutics, Inc. formerly known as?
Compass Therapeutics, Inc. was formerly known as Olivia Ventures, Inc.
On what date did the company change its name from Olivia Ventures, Inc.?
The company changed its name on April 19, 2018.
Where are Compass Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 80 Guest Street, Suite 601, Boston, Massachusetts 02135.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-01-08 08:00:37
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CMPX NASDAQ Capital
- $127 million — arketable securities were approximately $127 million as of December 31, 2024. This amount is
Filing Documents
- f8k_010725.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-25-000116.txt ( ) — 225KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_010725_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. The information contained in Item 8.01 of this Current Report, to the extent required, is incorporated into this Item 2.02 by reference.
01. Other Events
Item 8.01. Other Events. On January 8, 2025, Compass Therapeutics, Inc. (the "Company") issued a press release titled "Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate ". A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company disclosed its estimate that cash, cash equivalents and marketable securities were approximately $127 million as of December 31, 2024. This amount is unaudited and preliminary and is subject to the completion of financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company's financial statements as of and for the year ended December 31, 2024.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 8, 2025 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: January 8, 2025 By: /s/ Neil Lerner Neil Lerner Vice President Finance